Effects of repeated tramadol and morphine administration on psychomotor and cognitive performance in opioid-dependent volunteers

Drug and Alcohol Dependence

Volumn 111, Issue 3, 2010, Pages 265-268

  Mintzer, Miriam Z ^a   Lanier, Ryan K ^a   Lofwall, Michelle R ^a   Bigelow, George E ^a   Strain, Eric C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cognitive; Dependence; Morphine; Opioid; Performance; Tramadol

Indexed keywords

MORPHINE; TRAMADOL;

ADULT; ARTICLE; BODY EQUILIBRIUM; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; LOW DRUG DOSE; MALE; MENTAL TASK; MOTOR COORDINATION; OPIATE ADDICTION; OUTCOME ASSESSMENT; PATTERN RECOGNITION; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL;

ADULT; COGNITION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MORPHINE; OPIOID-RELATED DISORDERS; PSYCHOMOTOR PERFORMANCE; REACTION TIME; TRAMADOL;

EID: 77957304595     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.05.002     Document Type: Article

References (47)

1. Barth H., Durra S., Giertz H., Goroll D., Flohe L. Long-term administration of the centrally acting analgesic tramadol did not induce dependence or tolerance. Pain 1987, 4:S231.
2. Bruera E., Macmillan K., Hanson J., MacDonald R.N. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 1989, 39:13-16.
3. Cami J., Lamas X., Farre M. Acute effects of tramadol in methadone-maintained volunteers. Drugs 1994, 47(Suppl. 1):39-43.
4. Carroll C.P., Walsh S.L., Bigelow G.E., Strain E.C., Preston K.L. Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans. Exp. Clin. Psychopharmacol. 2006, 14:109-120.
5. Desmeules J.A., Piguet V., Collart L., Dayer P. Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br. J. Clin. Pharmacol. 1996, 41:7-12.
6. Driessen B., Reimann W., Giertz H. Effects of the central analgesic tramadol on the uptake and release of noradrenaline and dopamine in vitro. Br. J. Pharmacol. 1993, 108:806-811.
7. Epstein D.H., Preston K.L., Jasinski D.R. Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol. Biol. Psychol. 2006, 73:90-99.
8. First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W., 1995. Structured Clinical Interview for DSM-IV Axis Disorders - Patient Edition (SCID-I/P, Version 2.0). Biometrics Research Department, New York State Psychiatric Institute, 722 West 168th Street, New York, New York.
9. Forrest W.H., Brown B.W., Brown C.R., Defalque R., Gold M., Gordon H.E., James K.E., Katz J., Mahler D.L., Schroff P., Teutsch G. Dextroamphetamine with morphine for the treatment of postoperative pain. N. Engl. J. Med. 1977, 296:712-715.
10. Friderichs E., Felgenhauer F., Jongschaap P., Osterloh G. Pharmacological studies on analgesia, dependence on and tolerance of tramadol, a potent analgetic drug (author's transl.). Arzneimittelforschung 1978, 28:122-134.
11. Frink M.C., Hennies H.H., Englberger W., Haurand M., Wilffert B. Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung 1996, 46:1029-1036.
12. Gillen C., Haurand M., Kobelt D.J., Wnendt S. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunynschmiedeberg's Arch. Pharmacol. 2000, 362:116-121.
13. Goodman L.A., Kruskal W.H. Measures of association for cross-classifications. J. Am. Stat. Assoc. 1954, 49:732-764.
14. Gutstein H., Akil H. Opioid analgesics. Goodman and Gilman's The Pharmacological Basis of Therapeutics 2001, 569-619. McGraw-Hill, New York. 10th ed. J. Hardman, L. Limbird (Eds.).
15. Halstead W.C. Brain and Intelligence 1947, University of Chicago Press, Chicago.
16. Hill J.L., Zacny J.P. Comparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in healthy volunteers. Psychopharmacology 2000, 152:31-39.
17. Jasinski D.R., Preston K.L., Sullivan J.T., Testa M. Abuse potential of oral tramadol. NIDA Res. Monogr. 1993, 132:103.
18. Jonides J., Schumacher E.H., Smith E.E., Lauber E.J., Awh E., Minoshima S., Koeppe R.A. Verbal working memory load affects regional brain activation as measured by PET. J. Cogn. Neurosci. 1997, 9:462-475.
19. Kayser V., Besson J.M., Guilbaud G. Evidence for a noradrenergic component in the antinociceptive effect of the analgesic agent tramadol in an animal model of clinical pain, the arthritic rat. Eur. J. Pharmacol. 1992, 224:83-88.
20. Keppel G. Design and Analysis: A Researcher's Handbook 1991, Englewood Cliffs, Prentice Hall. 3rd edn.
21. Kleykamp B.A., Griffiths R.R., Mintzer M.Z. Dose effects of triazolam and alcohol on cognitive performance in healthy volunteers. Exp. Clin. Psychopharmacol. 2010, 18:1-16.
22. Lofwall M.R., Walsh S.L., Bigelow G.E., Strain E.C. Modest opioid withdrawal suppression efficacy of oral tramadol in humans. Psychopharmacology 2007, 194:381-393.
23. McLeod D.R., Griffiths R.R., Bigelow G.E., Yingling J. An automated version of the digit symbol substitution test (DSST). Behav. Res. Methods Instrum. Comput. 1982, 14:463-466.
24. Mintzer M.Z., Copersino M.L., Stitzer M.L. Opioid abuse and cognitive performance. Drug Alcohol Depend. 2005, 78:225-230.
25. Mintzer M.Z., Frey J.M., Yingling J.E., Griffiths R.R. Triazolam and zolpidem: a comparison of their psychomotor, cognitive, and subjective effects in healthy volunteers. Behav. Pharmacol. 1997, 8:561-574.
26. Mintzer M.Z., Stitzer M.L. Cognitive impairment in methadone maintenance patients. Drug Alcohol Depend. 2002, 67:41-51.
27. Murano T., Yamamoto H., Endo N., Kudo Y., Okada N., Masuda Y., Yano I. Studies on dependence on tramadol in rats. Arzneimittelforschung 1978, 28:152-158.
28. Preston K.L., Jasinski D.R. Effects of tramadol in humans: assessment of its abuse potential. NIDA Res. Monogr. 1989, 95:392.
29. Preston K.L., Jasinski D.R., Testa M. Abuse potential and pharmacological comparison of tramadol and morphine. Drug Alcohol. Depend. 1991, 27:7-17.
30. Raffa R.B. Basic pharmacology relevant to drug abuse assessment: tramadol as example. J. Clin. Pharm. Ther. 2008, 33:101-108.
31. Raffa R.B., Friderichs E., Reimann W., Shank R.P., Codd E.E., Vaught J.L. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J. Pharmacol. Exp. Ther. 1992, 260:275-285.
32. Raffa R.B., Friderichs E., Reimann W., Shank R.P., Codd E.E., Vaught J.L., Jacoby H.I., Selve N. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J. Pharmacol. Exp. Ther. 1993, 267:331-340.
33. Reitan R.M. Investigation of the validity of Halstead's measure of biological intelligence. Arch. Neurol. Psychiatry 1955, 73:28-35.
34. Salehi M., Amanatkar M., Barekatain M. Tramadol versus methadone for the management of acute opioid withdrawal: an add-on study. J. Res. Med. Sci. 2005, 11:185-189.
35. Snodgrass J.G., Corwin J. Pragmatics of measuring recognition memory: applications to dementia and amnesia. J. Exp. Psychol. Gen. 1988, 117:34-50.
36. Sobey P.W., Parran T.V., Grey S.F., Adelman C.L., Yu J. The use of tramadol for acute heroin withdrawal: a comparison to clonidine. J. Addict. Dis. 2003, 22:13-25.
37. Strain E.C., Stoller K., Walsh S.L., Bigelow G.E. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology 2000, 148:374-383.
38. Tamaskar R., Parran T.V., Heggi A., Brateanu A., Rabb M., Yu J. Tramadol versus buprenorphine for the treatment of opiate withdrawal: a retrospective cohort control study. J. Addict. Dis. 2003, 22:5-12.
39. Threlkeld M., Parran T.V., Adelman C.A., Grey S.F., Yu J. Tramadol versus buprenorphine for the management of acute heroin withdrawal: a retrospective matched cohort controlled study. Am. J. Addict. 2006, 15:186-191.
40. Wikler A., Haertzen C.A., Chessick R.D., Hill H.E., Pescor F.T. Reaction time (" mental set" ) in control and chronic schizophrenic subjects and in postaddicts under placebo. LSD-25, morphine, pentobarbital and amphetamine. Psychopharmacologia 1965, 7:423-443.
41. Yanagita T. Drug dependence potential of 1-(m-methoxyphenyl)-2-dimethylaminomethyl)-cyclohexan-1-ol hydrochloride (tramadol) tested in monkeys. Arzneimittelforschung 1978, 28:158-163.
42. Zacny J.P. A review of the effects of opioids on psychomotor and cognitive functioning in humans. Exp. Clin. Psychopharmacol. 1995, 3:432-466.
43. Zacny J.P. Profiling the subjective, psychomotor, and physiological effects of tramadol in recreational drug users. Drug Alcohol Depend. 2005, 80:273-278.
44. Zacny J.P., Conley K., Marks S. Comparing the subjective, psychomotor and physiological effects of intravenous nalbuphine and morphine in healthy volunteers. J. Pharmacol. Exp. Ther. 1997, 280:1159-1169.
45. Zacny J.P., Hill J.L., Black M.L., Sadeghi P. Comparing the subjective, psychomotor and physiological effects of intravenous pentazocine and morphine in normal volunteers. J. Pharmacol. Exp. Ther. 1998, 286:1197-1207.
46. Zacny J.P., Lichtor J.L., Flemming D., Coalson D.W., Thompson W.K. A dose-response analysis of the subjective, psychomotor and physiological effects of intravenous morphine in healthy volunteers. J. Pharmacol. Exp. Ther. 1994, 268:1-9.
47. Zacny J.P., Lichtor J.L., Thapar P., Coalson D.W., Flemming D., Thompson W.K. Comparing the subjective, psychomotor and physiological effects of intravenous butorphanol and morphine in healthy volunteers. J. Pharmacol. Exp. Ther. 1994, 270:579-588.